DOPEZIL is indicated for the treatment of dementia (e.g. impairment of memory, judgement, and abstract thinking; changes in personality) in patients with moderate to severe Alzheimer disease.
DOPEZIL is a cholinesterase inhibitor. It works by increasing the amount of a certain substance (acetylcholine) in the brain, which may help reduce the symptoms of dementia in patients with Alzheimer disease.
After a single oral dose of donepezil, peak plasma concentration is reached in 3 to 5 hours. It is well absorbed and has a bioavailability of 100%; this percentage is not affected by the time of day or food intake. It is extensively metabolized by the hepatic isoenzymes CYP2D6 and CYP3A4. Absorption and excretion rates of DOPEZIL are slower in elderly than in younger one but dose modification is not considered to be necessary in the elderly.
For the moderate Alzheimer’s disease, the recommended starting dosage is 5mg administered once per day in the evening, just prior to retiring which may be extended to 10mg per day. A dose of 10 mg should not be administered until patients have on a daily dose of 5mg for 4 to 6 weeks. For the moderate to severe Alzheimer’s disease, the recommended starting dosage of DOPEZIL is 5 mg administered once per day in the evening, just prior to retiring. The maximum recommended dosage of DOPEZIL in patients with moderate to severe Alzheimer’s disease is 23mg per day. A dose of 10mg should be administered until patients have been on a daily dose of 5mg for 4 to 6 weeks. A dose of 23 mg per day should not be administered until patients have been on a daily dose of 10 mg for at least 3 months.
Each strip contains 10 * 10s